UY37589A - COMPUESTOS MODULADORES DEL RECEPTOR DE HIDROCARBUROS ARÍLICOS (AhR) - Google Patents
COMPUESTOS MODULADORES DEL RECEPTOR DE HIDROCARBUROS ARÍLICOS (AhR)Info
- Publication number
- UY37589A UY37589A UY0001037589A UY37589A UY37589A UY 37589 A UY37589 A UY 37589A UY 0001037589 A UY0001037589 A UY 0001037589A UY 37589 A UY37589 A UY 37589A UY 37589 A UY37589 A UY 37589A
- Authority
- UY
- Uruguay
- Prior art keywords
- ahr
- arylic
- modulating compounds
- compounds
- hydrocarbon
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 239000004215 Carbon black (E152) Substances 0.000 title abstract 2
- 229930195733 hydrocarbon Natural products 0.000 title abstract 2
- 150000002430 hydrocarbons Chemical class 0.000 title 1
- 102000003984 Aryl Hydrocarbon Receptors Human genes 0.000 abstract 1
- 108090000448 Aryl Hydrocarbon Receptors Proteins 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- -1 aryl hydrocarbon Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Abstract
Compuestos que pueden actuar como moduladores del receptor de hidrocarburo arílico (AhR) y, en particular, como antagonistas de AhR. La invención además se relaciona con el uso de los compuestos para el tratamiento y/o la profilaxis de enfermedades y/o condiciones a través de la unión a dicho receptor de hidrocarburo arílico por parte de dichos compuestos.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17000158 | 2017-02-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY37589A true UY37589A (es) | 2018-02-28 |
Family
ID=57960223
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY0001037589A UY37589A (es) | 2017-02-01 | 2018-01-31 | COMPUESTOS MODULADORES DEL RECEPTOR DE HIDROCARBUROS ARÍLICOS (AhR) |
Country Status (28)
Country | Link |
---|---|
US (1) | US10981908B2 (es) |
EP (1) | EP3577112B1 (es) |
JP (1) | JP6849823B2 (es) |
KR (1) | KR102320516B1 (es) |
CN (1) | CN110248940B (es) |
AR (1) | AR110789A1 (es) |
AU (1) | AU2018216957B2 (es) |
BR (1) | BR112019015716A2 (es) |
CA (1) | CA3050827C (es) |
CL (1) | CL2019002108A1 (es) |
CO (1) | CO2019007881A2 (es) |
CR (1) | CR20190392A (es) |
CU (1) | CU20190069A7 (es) |
EA (1) | EA038318B1 (es) |
EC (1) | ECSP19055169A (es) |
ES (1) | ES2858329T3 (es) |
IL (1) | IL268080B (es) |
MX (1) | MX2019008994A (es) |
MY (1) | MY196831A (es) |
NI (1) | NI201900076A (es) |
PE (1) | PE20191478A1 (es) |
PH (1) | PH12019550135A1 (es) |
SG (1) | SG11201906958TA (es) |
TW (1) | TWI752155B (es) |
UA (1) | UA122745C2 (es) |
UY (1) | UY37589A (es) |
WO (1) | WO2018141857A1 (es) |
ZA (1) | ZA201904771B (es) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI752155B (zh) | 2017-02-01 | 2022-01-11 | 德商菲尼克斯製藥股份有限公司 | 芳香烴受體(AhR)調節劑化合物 |
TWI674260B (zh) * | 2017-02-01 | 2019-10-11 | 德商菲尼克斯製藥股份有限公司 | 芳基烴受體(AhR)調節劑化合物 |
US10815250B2 (en) | 2018-02-06 | 2020-10-27 | Ideaya Biosciences, Inc. | AhR modulators |
WO2020021024A1 (en) * | 2018-07-26 | 2020-01-30 | Phenex Pharmaceuticals Ag | Substituted bicyclic compounds as modulators of the aryl hydrocarbon receptor (ahr) |
SG11202105213XA (en) * | 2018-11-30 | 2021-06-29 | Celularity Inc | Expansion of natural killer cells and ilc3 cells with novel aromatic compounds |
EP4093739A1 (en) * | 2020-01-23 | 2022-11-30 | Phenex Pharmaceuticals AG | Oxalamide substituted heterocyclic compounds as modulators of the aryl hydrocarbon receptor (ahr) |
EP4110778A1 (en) | 2020-02-26 | 2023-01-04 | Jaguahr Therapeutics Pte Ltd | Pyridopyrimidine derivatives useful in modulation of ahr signalling |
US20230234967A1 (en) * | 2020-05-28 | 2023-07-27 | Senda Biosciences, Inc. | Fused Azole Heterocycles as AHR Antagonists |
CN114181212B (zh) * | 2020-09-15 | 2023-06-06 | 山东轩竹医药科技有限公司 | 哒嗪酮类AhR抑制剂 |
CN114835687B (zh) * | 2021-04-02 | 2023-09-05 | 北京华森英诺生物科技有限公司 | AhR抑制剂 |
CN115572282A (zh) * | 2021-07-05 | 2023-01-06 | 华东理工大学 | 含芳杂环结构的吡唑酰胺类化合物及其制备方法和应用 |
WO2024076300A1 (en) | 2022-10-03 | 2024-04-11 | Jaguahr Therapeutics Pte Ltd | Compounds useful in modulation of ahr signalling |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU8225991A (en) | 1990-07-31 | 1992-03-02 | Teikoku Hormone Mfg. Co., Ltd. | 2-phenylindole derivative |
DE69728688T2 (de) * | 1996-11-19 | 2004-08-19 | Amgen Inc., Thousand Oaks | Aryl und heteroaryl substituierte kondensierte pyrrole als entzündunghemmende mittel |
AU2003270426A1 (en) | 2002-09-12 | 2004-04-30 | Avanir Pharmaceuticals | PHENYL-INDOLE COMPOUNDS FOR MODULATING IgE AND INHIBITING CELLULAR PROLIFERATION |
US20050032869A1 (en) | 2003-07-08 | 2005-02-10 | Pharmacia Italia S.P.A. | Pyrazolyl-indole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
KR101007489B1 (ko) | 2005-11-18 | 2011-01-12 | 에프. 호프만-라 로슈 아게 | 아자인돌-2-카복스아마이드 유도체 |
US8563573B2 (en) * | 2007-11-02 | 2013-10-22 | Vertex Pharmaceuticals Incorporated | Azaindole derivatives as CFTR modulators |
ES2749504T3 (es) | 2009-10-13 | 2020-03-20 | Ligand Pharm Inc | Compuestos de moléculas pequeñas miméticos del factor de crecimiento hematopoyético y sus usos |
US20130338201A1 (en) * | 2009-11-02 | 2013-12-19 | Ahr Pharmaceuticals, Inc. | Method of Cancer Treatment with 2-(1H-Indole-3-Carbonyl)-Thiazole-4-Carboxylic Acid Methyl Ester |
JP5598775B2 (ja) * | 2009-11-02 | 2014-10-01 | ソン,ジャシェン | 癌の介入治療および根絶のためのiteとその類似体を含む医薬組成物 |
WO2011097079A1 (en) | 2010-02-03 | 2011-08-11 | Takeda Pharmaceutical Company Limited | Apoptosis signal-regulating kinase 1 inhibitors |
US8410117B2 (en) * | 2010-03-26 | 2013-04-02 | Hoffmann-La Roche Inc. | Imidazopyrimidine derivatives |
TWI619713B (zh) | 2010-04-21 | 2018-04-01 | 普雷辛肯公司 | 用於激酶調節的化合物和方法及其適應症 |
WO2012015914A2 (en) | 2010-07-27 | 2012-02-02 | Trustees Of Boston University | Aryl hydrocarbon receptor (ahr) modifiers as novel cancer therapeutics |
GB201104267D0 (en) | 2011-03-14 | 2011-04-27 | Cancer Rec Tech Ltd | Pyrrolopyridineamino derivatives |
KR20150070290A (ko) | 2012-10-17 | 2015-06-24 | 에프. 호프만-라 로슈 아게 | Trp 채널 길항제로서의 6-아미노인돌 유도체 |
KR102212923B1 (ko) | 2012-12-21 | 2021-02-04 | 플렉시콘 인코퍼레이티드 | 키나제 조절을 위한 화합물 및 방법, 및 그에 대한 적응증 |
TWI752155B (zh) | 2017-02-01 | 2022-01-11 | 德商菲尼克斯製藥股份有限公司 | 芳香烴受體(AhR)調節劑化合物 |
TWI674260B (zh) | 2017-02-01 | 2019-10-11 | 德商菲尼克斯製藥股份有限公司 | 芳基烴受體(AhR)調節劑化合物 |
TW201835070A (zh) | 2017-02-21 | 2018-10-01 | 德商菲尼克斯製藥股份有限公司 | 芳香烴受體(AhR)調節劑化合物 |
-
2018
- 2018-01-26 TW TW107102803A patent/TWI752155B/zh active
- 2018-01-31 UY UY0001037589A patent/UY37589A/es not_active Application Discontinuation
- 2018-01-31 AR ARP180100227A patent/AR110789A1/es unknown
- 2018-02-01 UA UAA201908353A patent/UA122745C2/uk unknown
- 2018-02-01 AU AU2018216957A patent/AU2018216957B2/en active Active
- 2018-02-01 ES ES18701774T patent/ES2858329T3/es active Active
- 2018-02-01 CR CR20190392A patent/CR20190392A/es unknown
- 2018-02-01 WO PCT/EP2018/052542 patent/WO2018141857A1/en unknown
- 2018-02-01 CN CN201880009354.9A patent/CN110248940B/zh active Active
- 2018-02-01 CU CU2019000069A patent/CU20190069A7/es unknown
- 2018-02-01 KR KR1020197023990A patent/KR102320516B1/ko active IP Right Grant
- 2018-02-01 US US16/479,130 patent/US10981908B2/en active Active
- 2018-02-01 BR BR112019015716-6A patent/BR112019015716A2/pt not_active IP Right Cessation
- 2018-02-01 SG SG11201906958TA patent/SG11201906958TA/en unknown
- 2018-02-01 JP JP2019561370A patent/JP6849823B2/ja active Active
- 2018-02-01 EP EP18701774.4A patent/EP3577112B1/en active Active
- 2018-02-01 MX MX2019008994A patent/MX2019008994A/es unknown
- 2018-02-01 MY MYPI2019004031A patent/MY196831A/en unknown
- 2018-02-01 CA CA3050827A patent/CA3050827C/en active Active
- 2018-02-01 EA EA201991599A patent/EA038318B1/ru unknown
- 2018-02-01 PE PE2019001482A patent/PE20191478A1/es unknown
-
2019
- 2019-07-15 IL IL268080A patent/IL268080B/en unknown
- 2019-07-15 NI NI201900076A patent/NI201900076A/es unknown
- 2019-07-19 ZA ZA2019/04771A patent/ZA201904771B/en unknown
- 2019-07-23 CO CONC2019/0007881A patent/CO2019007881A2/es unknown
- 2019-07-24 PH PH12019550135A patent/PH12019550135A1/en unknown
- 2019-07-29 CL CL2019002108A patent/CL2019002108A1/es unknown
- 2019-07-31 EC ECSENADI201955169A patent/ECSP19055169A/es unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY37589A (es) | COMPUESTOS MODULADORES DEL RECEPTOR DE HIDROCARBUROS ARÍLICOS (AhR) | |
UY37610A (es) | Compuestos moduladores del receptor de hidrocarburos de arilo (ahr) | |
UY37590A (es) | COMPUESTOS MODULADORES DEL RECEPTOR DE HIDROCARBUROS ARÍLICOS (AhR) | |
CL2019003015A1 (es) | Inhibidores del receptor de hidrocarburos de arilo (ahr) de indol y usos de los mismos. | |
CO2020016619A2 (es) | Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso | |
EA201891209A1 (ru) | Модуляторы хемокиновых рецепторов | |
UY37134A (es) | Compuestos heteroarilos y composiciones que los contienen útiles como inhibidores de pad4 | |
CL2017001289A1 (es) | Compuestos bicíclicos fusionados, sus composiciones y su uso para el tratamiento de enfermedades relacionadas con la modulación del receptor x farnesoide (fxr). | |
CL2016002021A1 (es) | Ciclopropilaminas como inhibidores lsd1. | |
AR102712A1 (es) | Agonistas parciales del receptor de insulina | |
CO7160047A2 (es) | Compuestos y composiciones que modulan la actividad del receptor del factor de crecimiento epidérmico (egfr) | |
ECSP18060342A (es) | Derivados de tiohidantoína sustituidos como antagonistas del receptor de andrógenos | |
CL2016002084A1 (es) | Compuestos derivados de ciclopentano 1,2 substituidos como antagonistas del receptor de orexina. | |
GT201700231A (es) | Azabenzimidazoles y su uso como moduladores del receptor ampa | |
PE20230683A1 (es) | Moduladores de receptor nuclear | |
CL2022001406A1 (es) | Aminoquinolonas sustituidas como inhibidores de dgk alfa para la activación inmune. | |
CL2016003074A1 (es) | Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer. | |
UY36348A (es) | Derivados de benzotiofenilo sustituidos como agonistas del gpr40 para el tratamiento de la diabetes tipo ii | |
DOP2016000212A (es) | Heterociclos condensados sustituidos como moduladores de gpr119 para el tratamiento de la diabetes, obesidad, dislipidemia y trastornos relacionados | |
CR20160557A (es) | Compuestos derivados de 1-(ciclopent-2-en-1-il)-3-(2-hidroxi-3-(arilsulfonil)fenil)urea como inhibidores cxcr2 | |
CL2019002873A1 (es) | Moduladores del receptor x del hígado (lxr). | |
EA202090732A1 (ru) | Составы для трансдермального введения | |
UY36217A (es) | Compuestos piridona sustituídos, composiciones farmacéuticas y métodos de uso. | |
ECSP16074207A (es) | Pirazinas moduladoras de gpr6 | |
CL2020002147A1 (es) | 3ß-(4-metoxibenciloxi)pregn-5-en-20-ona para su uso en el tratamiento de los trastornos relacionados con los cannabinoides. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
109 | Application deemed to be withdrawn |
Effective date: 20231026 |